nagourney, page-3

Dodge , sorry for the late reply . Have been busy . OK, Solbec has about 160 million 20c options as of september this year with two years to run .
Where I see the value in this company is its very low market cap at present . About $21.5 million dollars . If you look at one test Dr Nagourney did with the original drug (BEC) as a stand alone treatment against the current chemos in combinations on NSCLC , the best was half as effective as BEC and most were only quarter as effective . These chemos included Taxol(sales $192 million) , Gemcitabine (sales $700 million) , Carboplatin (sales $700 million ) and many others .
The Rational Therapeutics tests did not include the immune reaction against the cancer that SBP002 promotes . The drug has also been improved since then .
The maket cap for Solbec is very , very low for what they have in my opinion . The market they are shooting fore is 1 Billion+ . Blockbuster territory .
Of the Australian drugs in developement only Progen had any partial response in phase 1 . It was one patient . Their market cap is $140 million . Others include Peplin with $57million , Psvida $185 million , Novogen $416million , Sirtex $132million , Alchemia $57million and I havnt even mentionned psoraisis , which is another huge market .
The phase one trials seem to be verifying what Dr Nagourney found . Positive reactions in a first phase 1 are rare , and from what I read in the West , they have seen a size reduction in some tumours and slowed growth rates . All with a market cap of $21.5 million .
I recon some time next year 20 cents will seem reeeal cheap for a Solbec share . IMHO
Cheers